Type 1 diabetes mellitus.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing disease mechanisms, staging, and management without original clinical data or systematic review methodology.
PubMed 28358037 · doi:10.1038/nrdp.2017.16
What was done
This paper is a Disease Primer review detailing the epidemiology, staging, pathophysiology, autoantibody biomarkers, and clinical management strategies for type 1 diabetes mellitus (T1DM).
What was found
The abstract provides no quantitative experimental results or statistical effect sizes. It describes T1DM as a T cell-mediated autoimmune destruction of pancreatic beta-cells categorized into three distinct stages based on glycemic status and symptoms. Identifiable autoantibodies targeting secretory granule proteins (insulin, GAD65, IA-2, and ZnT8) emerge months to years prior to clinical onset. Despite advancements in intensive insulin delivery and continuous glucose monitoring, the abstract notes that a majority of patients continue to develop macrovascular and microvascular complications.
Why it matters
It provides a standardized conceptual framework for understanding the preclinical and symptomatic stages of type 1 diabetes, highlighting the diagnostic utility of islet autoantibodies and the persistent clinical burden of long-term complications.
Limits
The abstract contains no primary data, sample size, comparator groups, or quantitative measurements. As a broad narrative overview, it does not detail specific study methodologies, risk of bias, or statistical precision for the interventions and diagnostic markers discussed.
Cited by
- supports Type 1 diabetes is an autoimmune condition caused by the immune system attacking and destroying the pancreas.